Ivan Trifunovich, Ph.D.
Ivan Trifunovich, Ph.D., is an established leader in the healthcare and life science industries, where he has held a number of executive positions and served as a strategic consultant to global multi-national companies. He was the Executive Chairman of Helicos Biosciences from October 2010 until September 2012. Previously, Dr. Trifunovich served as the Senior Vice President of Third Wave Technologies, Inc., a molecular diagnostics company, from December 2001 through August 2008. Prior to joining Third Wave Technologies, Inc., Dr. Trifunovich held successive positions of increasing responsibility in sales and marketing and R&D with large pharmaceutical companies. During his tenure in large pharma, he was the named inventor on multiple patents related to the semi-synthesis of TAXOL(R). Dr. Trifunovich received his Ph.D. in organic chemistry at UCLA and an M.B.A. at the University of Pennsylvania's Wharton School of Business.
President, Chief Executive Officer and Director
Dr. Carlson has substantial leadership experience from startup to full P&L line management, sales and marketing, business and new product development, distribution management, and international operations. Prior to joining WaferGen in May 2015 as Chief Executive Officer Dr. Carlson served as President & CEO of Asuragen, Inc., a privately-held molecular diagnostics company. While at Asuragen, Inc., Dr. Carlson was a co-founder of Mirna Therapeutics, a spin-out of Asuragen, which has developed novel miRNA-based therapeutics currently in Phase I clinical trials for liver and other cancers. Prior to this, he served in increasingly senior positions at Abbott Laboratories over a 20-year period. Dr. Carlson's various roles at Abbott included Global General Manager and Vice President Molecular Diagnostics of Vysis, a wholly-owned subsidiary of Abbott Laboratories. Dr. Carlson also established strategic alliances with Genentech, Roche and Novartis. His last position at Abbott was Vice President, Business Development & Licensing, Global Medical Products, where he was responsible for M&A, licensing and divestiture of pharmaceutical products linked to medical device technologies. Dr. Carlson received his Ph.D. in Botany from Southern Illinois University at Carbondale.
Lead Independent Director
Joel Kanter has been in the financial services industry for over three decades and has focused on providing equity and bridge financing to small- and mid-sized companies, and institutional financing to mature enterprises. He has served as President of Windy City, Inc., a privately held investment firm, and as the Chief Executive Officer and President of Walnut Financial Services, Inc., a publicly traded company. Mr. Kanter serves on the Board of Directors of several public and privately held companies: Aquamatrix, Inc., Echo Healthcare Acquisition Corp., Modigene, Inc., I-Flow Corporation, Magna-Lab, Inc.
Mr. Kanter has a B.A. in political science and a B.A. in psychology from Tulane University.
R. Dean Hautamaki, M.D.
Dr. Hautamaki has served as our director since the closing of the Merger. Dr. Hautamaki is a practicing physician and since January 2005 has been the Assistant Clinical Professor of Medicine at the Florida State University College of Medicine in Tallahassee, Florida. From September 2003 to December 2005, Dr. Hautamaki is the Chairman of the Department of Medicine at Sarasota Memorial Hospital in Sarasota, Florida. From September 1997 through December 2005, he was a partner at Lung Associates of Sarasota in Sarasota, Florida. Dr. Hautamaki has authored over 12 papers and presented in several conferences.
Mr. Kaneshiro has served as director of WaferGen since March 2005. Mr. Kaneshiro is a founding member of Genetic Devices, Co., Ltd. in Japan and prior to that was the Executive Director of Overseas Investment for CSK Venture Capital Co., Ltd., where he had been since 2001. Previously, Mr. Kaneshiro was Executive Vice President of Sega.com and Sega of America. Before Sega, he was with the business development and corporate planning team of Sony Corporation of America. From 2003 to 2004, Mr. Kaneshiro was a member of the Board of Directors of Sega Corporation, a publicly traded company in Japan. He holds an MBA from Yale University.
Robert Schueren has held leadership positions in life science and diagnostic companies for more than two decades. Since April 2013, Mr. Schueren has been the Chief Executive Officer of IntegenX and a member of its Board of Directors. Previously he was Vice President and General Manager, Genomics for Agilent Technologies, where he oversaw a several hundred million dollar product portfolio, including the creation and successful commercialization of SureSelectTM. Prior to joining Agilent in 2010, he was the Global Head of Clinical Biomarkers and Operations, and Deputy Global Head of Molecular Medicine Labs for Genentech, Inc., a company he joined in 2006.
Mr. Schueren holds a B.S. degree in Pharmacy from Temple University.
William McKenzie has over 25 years of experience building new businesses in the global life sciences and diagnostics sectors. Most recently, Mr. McKenzie served as Vice President and General Manager of Molecular Diagnostics at PerkinElmer, Inc. from June, 2010 until December 2012. Previously he served in various other senior roles at PerkinElmer after joining the company in 2005, including serving as Business Development Director then Strategic Marketing Director of Molecular Medicine, and then as Global Business Director of Genetic Screening. Prior to PerkinElmer, Mr. McKenzie worked for more than 12 years in positions of increasing responsibility at Millipore.
Mr. McKenzie holds a M.S. degree in Biology from the University of Massachusetts, Boston.